Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
Rapport
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest Tweets
04:26pFDA approves Gilead cancer gene therapy; price set at $373,000  
04:23pThe FDA approves the Gilead's Yescarta lymphoma cancer therapy drug
1
04:17pFDA approves Gilead cancer gene therapy; price set at $373,000
1
04:14pMove over, Novartis: Kite and Gilead break into CAR-T market with early axi-c.. 
04:10pFDA approves Gilead cancer gene therapy; price set at $373,000
2
03:51pPharmalot.. Pharmalittle.. Good Morning.. Novo pins hopes on newly approved d.. 
03:47pOn The Fly: Pre-market Movers $VZ $DHR $BX $DGX $LLNW $URI $GILD $BLFS $ONCE .. 
03:40p#Stocks to Watch today: $VZ, $AXP, $NKE, $APRN, $GILD
5
03:37pGilead Jumps After FDA Approves Its Kite-Acquired CAR-T Drug
1
03:30pFDA approves Gilead cancer gene therapy; price set at $373,000
1
03:25pICYMI: $GILD breaks into CAR-T market with Yescarta approval  
03:17pmorning game plan. $ADBE $GILD $EBAY $UAL to watch our am meeting live ??
1
03:15pGilead Sciences shares bolstered after FDA approval validates Kite Pharma mer.. 
03:02pMorning Movers: Gilead Gains, Nike Drops, Philip Morris Tumbles  
03:00p  
02:53pPre-mkt movers/news | via CNBC $ADBE $UAL $EBAY $APRN $TSM $TRV $VZ $NKE $BX..
1
02:50pFDA approves Gilead cancer gene therapy; price set at $373,000
35
02:46pFDA approves Gilead cancer gene therapy; price set at $373,000
8
02:35pU.S. FDA approves Gilead cancer gene therapy; price set at $373,000
2
02:35p22 Stocks Moving In Thursday's PreMarket
3
02:35pFDA approves Gilead cancer gene therapy; price set at $373,000
9
02:26pBuying in Gilead (Kite Pharma) spreads to Juno, up 2% premarket  
02:21pGilead Sciences's buy rating reiterated at Berenberg Bank. $96.00 PT.  
02:16pVerizon Communications, Gilead Sciences, Alcoa Corp, PayPal Holdings - PRE-MA.. 
02:13p$GILD (+2.0% pre) FDA follows through with a groundbreaking OK for Yescarta, ..
1
02:10pGilead faces patent battle with Juno over Yescarta, says Morgan Stanley $JUNO..
1
01:58p"He refused The Handmaid’s Tale, too – presumably because those Gilead robes ..
1
01:43pWe discuss $GILD Yescarta approval, coming up on @SquawkCNBC 
01:38pBerenberg Bank Releases a Buy Rating on Gilead Sciences $GILD  
01:16p$GILD gets FDA approval for CAR-T cell based gene therapy, shares moving up $..
1
01:10p  
01:00p  
12:56pGilead shares rise 3% on FDA approval of cell therapy #news 
12:46p$GILD – Jan. $85 Call OI to 36,924 from 22,316 - mostly bought last 5 minute..
6
10:59aGilead Sciences, Inc. $GILD Shares Bought by Legal & General Group Plc  
10:55aBar Harbor Trust Services Has $355,000 Position in Gilead Sciences, Inc. $GIL.. 
10:55aStelac Advisory Services LLC Has $745,000 Holdings in Gilead Sciences, Inc. $.. 
10:29aSlight change to Zuma-1 remission data in Yescarta label (independent review)..
1
10:10aU.S. FDA approves Gilead cancer gene therapy; price set at $373,000
23
09:30aU.S. FDA approves Gilead cancer gene therapy; price set at $373,000
5
08:47aU.S. #FDA approves #Gilead #CAR-T #cancer gene therapy; price set at $373,000..
2
08:42aThe complex cell therapy will sell for $373,000:
7
07:40aGet Carta? Yescarta! $KITE $GILD
1
07:00aU.S. FDA approves Gilead cancer gene therapy; price set at $373,000
64
06:59aGilead’s $11 billion bet on buying Kite Pharma is poised to pay off
20
06:10aU.S. FDA approves Gilead cancer gene therapy; price set at $373,000
15
05:35aU.S. FDA approves Gilead cancer gene therapy; price set at $373,000
2
05:03aGilead cell-therapy drug Yescarta gets FDA approval  
04:30aU.S. FDA approves Gilead cancer gene therapy; price set at $373,000
4
04:30aU.S. FDA approves Gilead cancer gene therapy; price set at $373,000
2
04:15aGilead's new cancer gene therapy has been approved by the FDA
13
04:10aU.S. FDA approves Gilead cancer gene therapy; price set at $373,000
14
03:03aDear sell-side analysts — “Say Yes to Yescarta” can no longer be used in your..
5
02:50aU.S. FDA approves Gilead cancer gene therapy; price set at $373,000
72
02:41aU.S. FDA approves Gilead cancer gene therapy; price set at $373,000
7
02:29aUPDATE 2-U.S. FDA approves Gilead cancer gene therapy; price set at $373,000 .. 
02:15aWho is Kite Pharma? Yescarta is owned by Gilead.
1
02:14aNice pop in $GILD A/H, $KITE deal already paying off...CAR-T names could run ..
6
02:10aGilead cancer immunotherapy wins U.S. approval with $373,000 price
2
01:51a$GILD Gilead Cell-Therapy Drug Yescarta Gets FDA Approval ? stock up 3% ah 
01:48a$GILD: Gilead Sciences' Kite confirms Yescarta FDA approval as first CAR T th..
1
01:40aGilead revs up CAR-T with FDA approval
1
01:40aGilead revs up CAR-T with FDA approval  
01:33aGilead new cancer therapy wins FDA approval — with $373,000 tag
6
01:33aGilead new cancer therapy wins FDA approval — with $373,000 tag  
01:33afastFT: Gilead new cancer therapy wins FDA approval — with $373,000 tag
8
01:32aFunny, $NVO gets a green light on blockbuster diabetes drug/ murmurs/ $GILD g.. 
01:28a#ovariancancer Gilead wins US approval for CART cancer therapy: Approval of t.. 
01:14aGilead cancer immunotherapy wins U.S. approval with $373,000 price
8
01:05aGilead Sciences : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update  
Next »
Qtime:395
Financials ($)
Sales 2017 25 859 M
EBIT 2017 16 072 M
Net income 2017 10 607 M
Debt 2017 12 394 M
Yield 2017 2,64%
P/E ratio 2017 10,00
P/E ratio 2018 12,11
EV / Sales 2017 4,52x
EV / Sales 2018 5,02x
Capitalization 104 B
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 84,2 $
Spread / Average Target 5,2%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES11.73%104 487
REGENERON PHARMACEUTICALS19.69%47 079
VERTEX PHARMACEUTICALS110.07%39 018
ACTELION23.81%29 869
GENMAB14.75%12 912
EXELIXIS, INC.84.64%8 091